PG 545

Drug Profile

PG 545

Alternative Names: PG545

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Progen Pharmaceuticals
  • Developer Medigen Biotechnology Corporation; Progen Pharmaceuticals Limited; TBG Diagnostics Limited
  • Class Antineoplastics; Glycosaminoglycans; Oligosaccharides; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Heparanase inhibitors; Intercellular signalling peptide and protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Hepatocellular carcinoma
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 22 Sep 2016 Progen Pharmaceuticals completes a phase I trial in Solid tumours in Australia (NCT02042781)
  • 21 Jan 2014 Phase-I clinical trials in Solid tumours (late-stage disease) in Australia (IV)
  • 28 Sep 2012 PG 545 is available for licensing (\www.progen-pharma.com\)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top